Jefferies Maintains a 'Buy' on WuXi PharmaTech (WX); Margins Feeling Pressure, But Demand is High
Tweet
Share
E-mailGet Alerts WX Hot Sheet
Price: $25.50 -0.27%
Rating Summary:
7 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
7 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Jefferies maintains a 'Buy' on WuXi PharmaTech (NYSE: WX) price target of $17.00.
Analyst, David Windley, said, "We believe customers ultimately prefer quality to price, and WX will be the "last man standing" when others cannot make the quality at low prices equation work. That said, that separation has not come yet. Management raised its revenue mid-point by $12M more than the 2Q upside, but did not reflect that raise in its EBIT targets. WX's growth profile and valuation remain attractive, in our opinion."
Current quarter EPS estimate raised from $0.28 to $0.30, FY12 from $1.17 to $1.27 and FY13 from $1.31 to $1.44.
For an analyst ratings summary and ratings history on WuXi PharmaTech click here. For more ratings news on WuXi PharmaTech click here.
Shares of WuXi PharmaTech closed at $14.78 yesterday.
Analyst, David Windley, said, "We believe customers ultimately prefer quality to price, and WX will be the "last man standing" when others cannot make the quality at low prices equation work. That said, that separation has not come yet. Management raised its revenue mid-point by $12M more than the 2Q upside, but did not reflect that raise in its EBIT targets. WX's growth profile and valuation remain attractive, in our opinion."
Current quarter EPS estimate raised from $0.28 to $0.30, FY12 from $1.17 to $1.27 and FY13 from $1.31 to $1.44.
For an analyst ratings summary and ratings history on WuXi PharmaTech click here. For more ratings news on WuXi PharmaTech click here.
Shares of WuXi PharmaTech closed at $14.78 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
- Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
- McGraw Hill (MH) PT Raised to $15 at UBS
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
